Editorial: Translational Insights Into Mechanisms and Therapy of Organ Dysfunction in Sepsis and Trauma.
作者信息
Radermacher Peter, Billiar Timothy R, Ghezzi Pietro, Martin Lukas, Thiemermann Christoph
机构信息
Institute for Anesthesiological Pathophysiology and Process Engineering, Ulm University Hospital, Ulm, Germany.
Department of Surgery, University of Pittsburgh, Pittsburgh, PA, United States.
出版信息
Front Immunol. 2020 Sep 25;11:1987. doi: 10.3389/fimmu.2020.01987. eCollection 2020.
Abstract
摘要
相似文献
1
Editorial: Translational Insights Into Mechanisms and Therapy of Organ Dysfunction in Sepsis and Trauma.社论：脓毒症和创伤中器官功能障碍的机制与治疗的转化性见解
Front Immunol. 2020 Sep 25;11:1987. doi: 10.3389/fimmu.2020.01987. eCollection 2020.
2
Editorial: Community series in translational insights into mechanisms and therapy of organ dysfunction in sepsis and trauma - volume III.社论：脓毒症和创伤中器官功能障碍机制与治疗的转化性见解系列——第三卷。
Front Immunol. 2024 Jul 11;15:1447892. doi: 10.3389/fimmu.2024.1447892. eCollection 2024.
3
Organ dysfunction following hemorrhage and sepsis: mechanisms and therapeutic approaches (Review).出血和脓毒症后的器官功能障碍：机制与治疗方法（综述）
Int J Mol Med. 1999 Dec;4(6):575-83. doi: 10.3892/ijmm.4.6.575.
4
[Clinical study and long-term evaluation of immunomodulation therapy on trauma, severe sepsis and multiple organ dysfunction syndrome patients].免疫调节疗法对创伤、严重脓毒症及多器官功能障碍综合征患者的临床研究与长期评估
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2006 Nov;18(11):653-6.
5
Difference between sepsis and trauma diagnosed as sensitive diagnostic criteria for disseminated intravascular coagulation.脓毒症与创伤之间的差异被诊断为弥散性血管内凝血的敏感诊断标准。
Thromb Haemost. 2008 Dec;100(6):958-9. doi: 10.1160/th08-10-0683.
6
[Multiple organ failure].[多器官功能衰竭]
Vestn Khir Im I I Grek. 2001;160(3):110-4.
7
Concise Review: Mesenchymal Stem (Stromal) Cells: Biology and Preclinical Evidence for Therapeutic Potential for Organ Dysfunction Following Trauma or Sepsis.简要综述：间充质干（基质）细胞：创伤或脓毒症后器官功能障碍治疗潜力的生物学及临床前证据
Stem Cells. 2017 Feb;35(2):316-324. doi: 10.1002/stem.2551. Epub 2017 Jan 19.
8
[Mechanisms and evaluation of multiple organ and system failure after trauma].[创伤后多器官和系统功能衰竭的机制与评估]
Rev Hosp Clin Fac Med Sao Paulo. 1996 Mar-Apr;51(2):72-7.
9
Editorial: Community series in translational insights into mechanisms and therapy of organ dysfunction in sepsis and trauma, volume II.社论：《脓毒症和创伤中器官功能障碍机制与治疗的转化见解社区系列》第二卷
Front Immunol. 2023 May 25;14:1215888. doi: 10.3389/fimmu.2023.1215888. eCollection 2023.
引用本文的文献
1
Value of animal sepsis research in navigating the translational labyrinth.动物脓毒症研究在跨越转化迷宫中的价值。
Front Immunol. 2025 Apr 15;16:1593342. doi: 10.3389/fimmu.2025.1593342. eCollection 2025.
2
RETRACTED: Etiological characteristics of wound infection in severe trauma patients and logistic regression analysis of influencing factors of infection.撤回：严重创伤患者伤口感染的病因特征及感染影响因素的logistic回归分析
Int Wound J. 2024 Feb;21(2):e14682. doi: 10.1111/iwj.14682.
3
[Current regulations in the Animal Welfare Act and the significance for animal research].[《动物福利法》中的现行规定及其对动物研究的意义]
Orthopadie (Heidelb). 2024 May;53(5):336-340. doi: 10.1007/s00132-024-04493-8. Epub 2024 Apr 5.
4
Multiorgan Dysfunction Syndrome in Abusive and Accidental Pediatric Traumatic Brain Injury.虐待和意外小儿创伤性脑损伤的多器官功能障碍综合征。
Neurocrit Care. 2024 Jun;40(3):1099-1108. doi: 10.1007/s12028-023-01887-y. Epub 2023 Dec 7.
5
Molecular Mechanisms of Ischaemia-Reperfusion Injury and Regeneration in the Liver-Shock and Surgery-Associated Changes.肝缺血再灌注损伤和再生的分子机制-休克和手术相关变化。
Int J Mol Sci. 2022 Oct 26;23(21):12942. doi: 10.3390/ijms232112942.
本文引用的文献
1
Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia.布鲁顿酪氨酸激酶抑制剂伊布替尼可减轻肺炎链球菌肺炎小鼠肺部的炎症性髓系细胞反应。
Mol Med. 2019 Jan 15;25(1):3. doi: 10.1186/s10020-018-0069-7.
2
Arguing for Adaptive Clinical Trials in Sepsis.关于脓毒症适应性临床试验的争论。
Front Immunol. 2018 Jun 28;9:1502. doi: 10.3389/fimmu.2018.01502. eCollection 2018.
3
The Yin and Yang of Tyrosine Kinase Inhibition During Experimental Polymicrobial Sepsis.实验性多微生物脓毒症期间酪氨酸激酶抑制的阴阳两面。
Front Immunol. 2018 Apr 30;9:901. doi: 10.3389/fimmu.2018.00901. eCollection 2018.
4
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.伊布替尼治疗伴有 17p 缺失的复发或难治性慢性淋巴细胞白血病患者（RESONATE-17）：一项 2 期、开放标签、多中心研究。
Lancet Oncol. 2016 Oct;17(10):1409-1418. doi: 10.1016/S1470-2045(16)30212-1. Epub 2016 Sep 13.
Zotero 插件